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Myocardial infarction (MI) is a major cause ofmorbidity and
mortality in the developed world [1,2]. The mortality risk in
women suffering from MI is higher than that in men [3]. One
obvious explanation for this disparity is that on average, women
are about 10 years older than men at the time of MI. Other
factors, such as gender bias in clinical approach toMI treatment
[4], inadequate MI diagnosis in women due to atypical
presentation [5], and lower rate of revascularization procedures
in women [6] have also been discussed to explain the
unfavorable outcome of MI in women.uthor at: 1. Medizinische Klinik, Klinikum rechts der
ersität München, Ismaninger Str. 22, 81675 München,
schmidt@tum.de
ting first authors.
ting senior authors.
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Authors. Published byElsevier Inc. This is an open access article unSex differences in the physiology of coronary artery disease
(CAD), such as a higher prevalence of non-obstructive CAD in
women [7], may also contribute to the outcome differences.
Furthermore, interventional treatments recommended by the
guidelines [1,2,8,9] might be less effective in females than in
males due to the smaller diameter of the coronary arteries in the
former [10].
Patients surviving the acute MI phase are at risk of
subsequent death due to re-infarction, arrhythmia, or heart
failure.Corresponding non-invasive risk predictors are presently
intensively researched [11]. While left-ventricular ejection
fraction remains the core of current post-MI risk assessment,
its limits are well recognized and several other parameters have
been evaluated for their potential to improve risk stratification
[11–18]. A systematic analysis of sex differences in the
predictive power of these parameters has not yet been reported.
This study re-assessed the mortality risk in contemporarily-
treated MI patients of either sex and investigated whether theder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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specific predictive models.Methods
Study cohort
The present study used data of patients enrolled in two
separate cohort studies, namely the ISAR study [19] and the
ART study [20]. Enrolment took place between January 1996
andMarch 2005 with last follow-up inMay 2010. Patients were
recruited at two centers inMunich (Klinikum rechts der Isar and
Deutsches Herzzentrum München). We included patients
suffering from acute MI within 4 weeks before enrolment. MI
diagnosis was defined as two or more of (i) chest pain for
≥20 min, (ii) creatine kinase-MB above the doubled upper
normal limit of our laboratory, (iii) ST-segment elevation of
0.1 mV in two ormore limb leads and/or 0.2 mV in two ormore
contiguous precordial leads at the time of hospital admission. In
the present analysis, we have not applied any upper age limit and
also included patients who were not in sinus rhythm.
The study consisted of two parts, dealing with sex
differences in the outcome (part A), and sex differences in
the power of risk predictors (part B). Fig. 1 shows the patient
flow. Part A involved all patients admitted to the hospital
with acute MI (cohort A), whereas part B included only
patients who (1) survived the first month after admission, (2)
had no indication for secondary prevention implantable
cardioverter/defibrillator (ICD) therapy, and (3) had a Holter
ECG available (cohort B).
For parts A and B, the primary endpoint was all-cause
mortality at 30 days and at 5 years, respectively.
The study was approved by the local ethics committee.
Oral (ISAR study) or written (ART study) informed consent
was obtained from all patients or from their legal caregivers.Fig. 1. Patient flow chart. (Color illustration online.) ICD: implantable
cardioverter/defibrillator.Clinical variables
At admission, a standard 12-lead ECG was recorded and
blood pressure, heart rate, serum creatinine and cardiac
enzymes were measured in all patients. Left ventricular
ejection fraction (LVEF) was quantified either by angiography
or by echocardiography. Patients were considered to have
diabetes if already diagnosed or if receiving treatment with
diet, oral medication or insulin or if fasting blood glucose
concentration repeatedly exceeded 11 mmol/L.
Holter and ECG variables
Holter ECGs were recorded during the initial hospitalization
for MI using equipment by Oxford instruments (n = 829, 3
channels), Reynolds Medical (n = 1925, 3 channels), and
Mortara Instrument (n = 197, 12 channels). The recordings
were automatically analyzed by corresponding analytical
systems. Subsequently, visual verification and, where appro-
priate, manual correction was made of QRS detections and
classifications (normal, ventricular ectopic, and supraventricular
ectopic) by experienced technicians.
Risk predictors derived from the Holter ECG included
mean heart rate, number of ventricular premature complexes
(VPCs) per hour, heart rate variability triangular index
(HRVTI) [12], heart rate turbulence [21] slope (TS) and
onset (TO), heart rate deceleration capacity (DC) [22], and
Holter-derived nocturnal respiratory rate [16,17]. QRS width
and corrected QT interval (QTc; calculated according Bazett's
formula) were obtained from a standard 12-lead ECGs.
Follow-up and endpoints
Clinical follow-up appointments were scheduled approxi-
mately every 6 months. If a patient did not attend a planned
appointment, contact was made via mail, telephone or through
the attending general practitioner. If none of these channels
were successful, the local population registry either provided a
new address of the patient or confirmed that the patient was
deceased. If a patient could neither be contacted nor his/her
death confirmed during the first year of follow-up, he/she was
considered lost to follow-up. If this happened later in follow-
up, the patient was censored at the time of last contact.
Statistics
Continuous variables are presented as median and inter-
quartile range (IQR). Categorical data are presented as
absolute frequencies and percentages. Survival curves were
estimated by the Kaplan–Meier method and compared using
the log-rank test. Univariable and multivariable Cox
proportional hazards models were used to assess the
association of predictors with mortality. Receiver-operator
characteristics (ROC) curves were used to evaluate the
predictive power of continuous parameters and risk scores
and quantified by calculating the area under the curve
(AUC). Optimum dichotomies of continuous variables were
determined as the maximum of the log-rank statistics. The
sensitivities achieved by the different models at a fixed
specificity of 90% were compared by the McNemar test [23].
A stepwise multivariable Cox regression was performed
separately in men and women to investigate whether sex
Table 1
Cohort A — Patient characteristics.
Variable Men n = 3043 Women
n = 1098
p
Clinical characteristics
Age (years), median (IQR) 62 (53–71) 70 (62–78) b0.0001
Diabetes mellitus, n (%) 603 (19.8%) 284 (25.9%) b0.0001
Hypertension, n (%) 1946 (64.0%) 807 (73.5%) b0.0001
Smokers, n (%) 1594 (52.4%) 290 (26.4%) b0.0001
Non-SR, n (%) 244 (8.0%) 118 (10.7%) 0.003
History of previous MI,
n (%)
420 (13.8%) 111 (10.1%) 0.002
CKmax (U/l), median (IQR) 1218 (582–2486) 944 (440–2018) b0.0001
LVEF (%), median (IQR) 53 (44–61) 54 (44–62) 0.374
Creatinine (mg/dl),
median (IQR)
1.2 (1.0–1.3) 1.0 (0.8–1.2) b0.0001
Therapy data
Intervention
PCI, n (%) 2731 (89.7%) 925 (84.2%) b0.0001
Thrombolysis, n (%) 64 (2.1%) 28 (2.6%) 0.389
CABG, n (%) 86 (2.8%) 30 (2.7%) 0.872
No intervention, n (%) 162 (5.3%) 115 (10.5%) b0.0001
Non-obstructive CAD 38 (1.2%) 54 (4.9%) b0.0001
ASS, n (%) 2877 (94.5%) 1025 (93.4%) 0.146
β-blockers, n (%) 2654 (87.2%) 945 (86.1%) 0.332
ACE inhibitors, n (%) 2598 (85.4%) 908 (82.7%) 0.035
Statins, n (%) 2466 (81.0%) 860 (78.3%) 0.052
Diuretics, n (%) 1240 (40.7%) 500 (45.5%) 0.006
Mortality data
30-day all-cause
mortality, n (%)
185 (6.1%) 102 (9.3%) b0.0001
5-year all-cause
mortality, n (%)
527 (17.3%) 277 (25.2%) b0.0001
IQR: inter-quartile range; SR: sinus rhythm; MI: myocardial infarction;
CK: creatine kinase; LVEF: left-ventricular ejection fraction; PCI: percutaneous
coronary intervention; CABG: coronary artery bypass grafting; CAD: coronary
artery disease; ASS: acetylsalicylic acid; ACE: angiotensin-converting enzyme.
Table 2
Multivariable Cox analysis for 30-day and 5-year all-cause mortality.
Variable χ2 HR (95% CI) p
30-day all-cause mortality
Female sex 1.7 1.18 (0.92–1.51) 0.188
Age ≥65 years 76.0 3.41 (2.59–4.50) b0.001
5-year all-cause mortality
Female sex 2.7 1.13 (0.98–1.31) 0.103
Age ≥65 years 268.5 4.02 (3.40–4.74) b0.001
HR: hazard ratio; CI: confidence interval.
Table 3
Cohort B — Patient characteristics.
Variable Men
n = 2227
Women
n = 724
p
Clinical characteristics
Age (years), median (IQR) 61 (52–69) 70 (60–77) b0.0001
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models. Differences were considered statistically significant
if p b 0.05. IBM SPSS Statistics 22.0 (IBM SPSS, Inc.) andFig. 2. Mortality probability over 5 years in patients stratified by sex. (Color
illustration online.)R 2.15.1 (R Foundation for Statistical Computing, Vienna,
Austria) were used for all statistical calculations.Results
The whole study cohort (cohort A) consisted of 4141
patients (26.5% females), cohort B consisted of 2951
patients (24.5% females). A patient flow chart of the study
is shown in Fig. 1.
Effect of sex on mortality
Clinical characteristics of cohort A are shown in Table 1.
The median age was 62 and 70 years in male and female
patients, respectively. Diabetes mellitus and hypertension
were more prevalent in women than in men, while men were
more frequently smokers and had more frequently a historyDiabetes mellitus, n (%) 419 (18.8%) 180 (24.9%) b0.0001
Hypertension, n (%) 1470 (60.0%) 543 (75.0%) b0.0001
Smokers, n (%) 1239 (55.6%) 210 (29.0%) b0.0001
Non-SR, n (%) 126 (5.7%) 58 (8.0%) 0.023
History of previousMI, n (%) 293 (13.2%) 69 (9.5%) 0.010
CK max (U/l), median (IQR) 1218 (594–2450) 956 (445–2040) b0.0001
LVEF (%), median (IQR) 53 (45–61) 55 (44–63) 0.226
Creatinine (mg/dl),
median (IQR)
1.1 (1.0–1.4) 1.0 (0.8–1.2) b0.0001
Therapy data
Intervention
PCI, n (%) 2051 (92.1%) 631 (87.2%) b0.0001
Thrombolysis, n (%) 54 (2.4%) 20 (2.8%) 0.614
CABG, n (%) 42 (1.9%) 15 (2.1%) 0.752
No intervention, n (%) 80 (3.6%) 58 (8.0%) b0.0001
ASS, n (%) 2179 (97.8%) 713 (98.5%) 0.288
β-blockers, n (%) 2065 (92.7%) 686 (94.8%) 0.060
ACE inhibitors, n (%) 2029 (91.1%) 654 (90.3%) 0.527
Statins, n (%) 1946 (87.4%) 625 (86.3%) 0.461
Diuretics, n (%) 971 (43.6%) 357 (49.3%) 0.007
Mortality data
5-year all-cause
mortality, n (%)
230 (10.3%) 118 (16.3%) b0.0001
IQR: inter-quartile range; SR: sinus rhythm; MI: myocardial infarction;
CK: creatine kinase; LVEF: left-ventricular ejection fraction; PCI: percutaneous
coronary intervention; CABG: coronary artery bypass grafting; ASS:
acetylsalicylic acid; ACE: angiotensin-converting enzyme
Women
Men
Fig. 3. Receiver-operating characteristics (ROC) analysis of predictors of 5-year all-cause mortality in male and female MI patients. Area under the curve (AUC
values and optimum dichotomies are depicted. LVEF: left-ventricular ejection fraction. VPC: ventricular premature complexes. HRT: heart rate turbulence. TO
turbulence onset. TS: turbulence slope. DC: deceleration capacity. HRVTI: heart rate variability triangular index. QTc: heart rate-corrected QT duration. (Colo
illustration online.)
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Table 4
Sex-specific multivariable Cox models for 5-year all-cause mortality.
Women (n = 724)
Variable χ2 HR (95% CI) p
Non-SR 37.6 7.64 (3.99–14.65) b0.001
Age ≥78 years 26.7 2.83 (1.91–4.20) b0.001
LVEF ≤30% 14.0 2.39 (1.51–3.77) b0.001
HRVTI ≤20 12.3 2.32 (1.45–3.71) b0.001
QRS ≥116 ms 5.8 1.84 (1.12–3.02) 0.016
DC ≤4.08 14.0 2.69 (1.60–4.52) b0.001
Men (n = 2227)
Variable χ2 HR (95% CI) p
Non-SR 24.8 3.24 (2.04–5.14) b0.001
Age ≥69 years 42.5 2.59 (1.95–3.45) b0.001
LVEF ≤30% 30.7 2.55 (1.83–3.54) b0.001
Mean heart rate ≥71 bpm 4.0 1.35 (1.01–1.82) 0.045
HRVTI ≤15 9.9 1.75 (1.23–2.48) 0.002
HRT: TO and TS abnormal 24.9 2.62 (1.80–3.83) b0.001
DC ≤3.32 10.5 1.73 (1.24–2.41) 0.001
CI: confidence interval; DC: deceleration capacity; SR: sinus rhythm;
LVEF: left-ventricular ejection fraction; HR: hazard ratio; HRT: heart rate
turbulence; HRVI: heart rate variability triangular index; SR: sinus rhythm;
TO: turbulence onset; TS: turbulence slope.
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male and female patients.
Coronary angiography was performed in 99.9% of male
and in 99.5%of female patients. The revascularization ratewas
significantly lower in women than in men (89.5% vs. 94.7%,
p b 0.0001). There were no significant sex differences in the
use of aspirin, β-blockers and statins. Female patients were
significantly less often treated with ACE inhibitors but more
frequently with diuretics.
Twenty-nine patients were lost to follow-up. Mortality
curves for patients stratified by sex are shown in Fig. 2. At
30 days, mortality rate was 9.3% in women and 6.1% in men
(p b 0.0001). At 5 years, these rates were 25.4% and 17.3%,
respectively (p b 0.001). When we restricted the latter
analysis to survivors of the initial hospital stay, these rates
were 17.6% and 12.0%, respectively (p b 0.0001).0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
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Fig. 4. Receiver-operating characteristics (ROC) analysis of sex-specific and sex-
female (A), in male (B) and in all (C) patients. Area under the curve (AUC) valueFemale sex was a significant predictor of the 30-day and 5-
year all-cause mortality in a univariable Cox analysis, with
hazard ratios of 1.55 (1.22–1.98) and 1.53 (1.33–1.77),
respectively (p b 0.001 for both). However, in multivariable
models adjusted for age, female sex was no longer significantly
associated with mortality (p = 0.188 and p = 0.103; Table 2).Sex differences in the prediction of long-term outcome
The clinical characteristics of cohort B are shown in
Table 3. As in cohort A, women were older, were more
frequently affected by diabetes and hypertension, and
received revascularization treatment less frequently (92.0%
vs. 96.4%, p b 0.0001).
There were marked sex differences in the AUC values of
ROC curves as well as in the optimum dichotomies of
investigated risk factors. For example, mean heart rate was a
stronger mortality predictor in men than in women (AUC
0.66 vs. 0.61), and the optimum separation between
survivors and non-survivors was achieved with a dichotomy
of ≥71 beats per minute (bpm) in men and ≥85 bpm in
women (see Fig. 3).
The sex-specific Cox regression models were not only
different in dichotomies but also in the independent variables
(Table 4). Moreover, the hazard ratios of some variables
differed largely between models. For example, the absence
of sinus rhythm was associated with a hazard ratio of 7.6 in
female and of 3.2 in male patients.
ROC curves for the performance of both sex-specific and
sex-neutral risk models in male and female patients and in
the complete study cohort are shown in Fig. 4. In women, the
sex-specific model performed better than the sex-neutral
model (AUC of 0.825 vs. 0.802, Fig. 4A). At a specificity of
90%, sensitivity increased significantly from 33.9% of the
sex-neutral model to 50.0% of the sex-specific model
(p b 0.001). In men, the predictive power of the sex-specific
model was practically identical with that of the sex-neutral
model (AUC of 0.805 vs. 0.799; Fig. 4B). In an analysis of
the entire cohort, the performance of the sex-specific model
was also only marginally better than that of the sex-neutral.5 0.6 0.7 0.8 0.9 1
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Table 5
Sensitivity, specificity, positive and negative predictive values of sex-
specific and sex-neutral risk models.
Risk stratification
criterion
e/n Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Men and women
Sex-neutral model 348/2951 (11.8%) 55.5 83.6 31.2 93.4
Sex-specific models 348/2951 (11.8%) 70.4 79.2 31.2 95.2
Men
Sex-neutral model 230/2227 (10.3%) 53.0 86.0 30.3 94.1
Sex-specific model 230/2227 (10.3%) 63.9 81.8 28.8 95.2
Women
Sex-neutral model 118/724 (16.3%) 60.2 75.9 32.7 90.7
Sex-specific model 118/724 (16.3%) 83.1 70.6 35.5 95.5
e/n: events/number of patients; PPV: positive predictive value; NPV: negative
predictive value.
879D. Sinnecker et al. / Journal of Electrocardiology 47 (2014) 874–880model (AUC of 0.815 vs. 0.809). Values of sensitivity,
specificity, positive and negative predictive values of sex-
specific and sex-neutral models are shown in Table 5. While
a sex-specific model resulted in better positive and negative
predictive values in women, these differences were almost
absent in the overall cohort.Discussion
The first aim of this study was to re-assess the mortality risk
in contemporarily-treated MI patients of either sex. We found
that 30-day mortality of female patients was 1.5-fold higher
than that of male patients. The excess mortality of women in
our cohort can be explained by their older age. After adjusting
for age, sex was no longer a significant mortality predictor.
Because of more advanced age at the time of MI, female
patients have a greater disease burden (exemplified by a higher
prevalence of diabetes, hypertension, and the absence of sinus
rhythm; see Table 1).
Our data do not support the assumption that inadequate
diagnostic efforts are responsible for the unfavorable
outcome in post-MI women. In our population the
percentage of coronary angiographies was high in both
female and male patients.
Earlier observations [6] indicated that the higher mortality
of female MI patients is caused by a lower revascularization
rate. However, in that study, the overall revascularization rate
was less than 10%, as compared to 93% in our cohort. In our
study, we also observed a significantly lower revascularization
rate in females (89.7% inmales versus 84.2% in females). This
may be explained by the higher prevalence of non-obstructive
CAD in women observed in this and another study [7].
However, treatment was left to the discretion of the
interventional cardiologist, and we cannot exclude that
decisions for or against revascularization were also influenced
by factors such as age or sex.
The second aim was to investigate whether the prediction
of poor outcome in survivors of the acute phase of MI can be
improved by sex-specific predictive models. To a certain
extent, the prognostic power of several risk factors differed
between male and female patients. Moreover, severaloptimum dichotomies differed markedly between men and
women. These differences led to a sex-specific risk model,
which in female patients performed better than a sex-neutral
model. If applied to the whole cohort, the improvement in
risk stratification by using sex-specific risk models was only
marginal. However, this may be explained by the lower
proportion of women in the complete cohort. We may thus
conclude that risk prediction in women might benefit from
sex-specific risk models.
Our study has also several limitations. Most importantly,
because of higher prevalence of MI in men, the number of
female patients in our study was more than 3 times lower than
that of male patients. Consequently, the calculations applied to
female patients had lower statistical power. The dichotomies
and the models for the prediction of 5-year mortality were
developed in the same cohort of patients to whom they were
applied. Thismight have resulted in over-optimization. The true
performance gain of a sex-specific model for female patients
might thus be smaller than we estimated.Acknowledgments
This work was supported by the Bundesministerium für
Bildung, Wissenschaft, Forschung und Technologie (German
Federal Ministry of Education and Research; 13N/7073/7), by
the Deutsche Forschungsgemeinschaft (German Research
Foundation; Si 1747/1-1), and by the 19,6 Millionen Klub e.
V. (a German nonprofit organization). The sponsors had no
role in study design, data collection, data analysis, data
interpretation, or writing of the report.References
[1] Task force on themanagement of ST-segment elevation acutemyocardial
infarction of the European Society of Cardiology (ESC). ESC guidelines
for the management of acute myocardial infarction in patients presenting
with ST-segment elevation. Eur Heart J 2012;33:2569–619.
[2] American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the
management of ST-elevation myocardial infarction. J Am Coll Cardiol
2013;61:e78–e140.
[3] Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI. Sex differences
in mortality after acute myocardial infarction: Is there evidence for an
increased risk for women? Circulation 1995;91:1861–71.
[4] Healy B. The Yentl syndrome. N Engl J Med 1991;325:274–6.
[5] Mackay MH, Ratner PA, Johnson JL, Humphries KH, Buller CE.
Gender differences in symptoms of myocardial ischemia. Eur Heart J
2011;32:3107–14.
[6] Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender
differences in hospital mortality and use of percutaneous coronary
intervention in acute myocardial infarction. Microsimulation analysis
of the 1999 nationwide French hospitals database. Circulation
2007;115:833–9.
[7] Bugiardini R, Bairey Merz CN. Angina with “normal” coronary
arteries: a changing philosophy. JAMA 2005;293:477–84.
[8] Task force for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation of
the European Society of Cardiology (ESC). ESC guidelines for
the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation. Eur Heart J
2011;32:2999–3054.
[9] American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines. 2012 ACCF/AHA focused update
incorporated into the ACCF/AHA 2007 guidelines for the management of
880 D. Sinnecker et al. / Journal of Electrocardiology 47 (2014) 874–880patients with unstable angina/non-ST-elevation myocardial infarction.
Circulation 2012;126:875–910.
[10] Sheifer SE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO,
Gersh BJ, et al. Sex differences in coronary artery size assessed by
intravascular ultrasound. Am Heart J 2000;139:649–53.
[11] Dagres N, Hindricks G. Risk stratification after myocardial infarction:
is left ventricular ejection fraction enough to prevent sudden cardiac
death? Eur Heart J 2013;34:1964–71.
[12] Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology. Heart rate
variability. Standards of measurement, physiological interpretation,
and clinical use. Eur Heart J 1996;17:354–81.
[13] Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de
Werf F, et al. A validated prediction model for all forms of acute
coronary syndrome: estimating the risk of 6-month postdischarge death
in an international registry. J Am Med Assoc 2004;291:2727–33.
[14] Verrier RL, Klingenheben T, Malik M, El-Sherif N, Exner DV,
Hohnloser SH, et al. Microvolt T-wave alternans: physiological basis,
methods of measurement, and clinical utility — consensus guideline
by International Society for Holter and Noninvasive Electrocardiology.
J Am Coll Cardiol 2011;58:1309–24.
[15] Wellens HJJ, Schwartz PJ, Lindemans FW, Buxton AE, Goldberger JJ,
Hohnloser SH, et al. Risk stratification for sudden cardiac death:
current status and challenges for the future. Eur Heart J 2014, http://dx.
doi.org/10.1093/eurheartj/ehu176.
[16] Dommasch M, Sinnecker D, Barthel P, Müller A, Dirschinger RJ,
Hapfelmeier A, et al. Nocturnal respiratory rate predicts non-suddencardiac death in survivors of acute myocardial infarction. J Am Coll
Cardiol 2014;63:2432–3.
[17] Sinnecker D, Dommasch M, Barthel P, Müller A, Dirschinger RJ,
Hapfelmeier A, et al. Assessment of mean respiratory rate from ECG
recordings for risk stratification aftermyocardial infarction. J Electrocardiol
2014, http://dx.doi.org/10.1016/j.jelectrocard.2014.04.021 [pii: S0022-
0736(14)00153-8, Epub ahead of print].
[18] Sinnecker D, Dirschinger RJ, Barthel P, Müller A, Morley-Davies A,
Hapfelmeier A, et al. Postextrasystolic blood pressure potentiation
predicts poor outcome of cardiac patients. J Am Heart Assoc 2014;3(3),
http://dx.doi.org/10.1161/JAHA.114.000857 [pii: e000857].
[19] Bauer A, Barthel P, Schneider R, Ulm K, Müller A, Joeinig A, et al.
Improved stratification of autonomic regulation for risk prediction in
post-infarction patients with preserved left ventricular ejection fraction
(ISAR-Risk). Eur Heart J 2009;30:576–83.
[20] Barthel P, Bauer A,Müller A, Huster KM,Kanters JK, Paruchuri V, et al.
Spontaneous baroreflex sensitivity: prospective validation trial of a novel
technique in survivors of acute myocardial infarction. Heart Rhythm
2012;8:1288–94.
[21] Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after
ventricular premature beats as a predictor of mortality after acute
myocardial infarction. Lancet 1999;353:1390–6.
[22] Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of
heart rate as a predictor of mortality after myocardial infarction: cohort
study. Lancet 2006;367:1674–81.
[23] McNemar Q. Note on the sampling error of the difference between
correlated proportions or percentages. Psychometrika 1947;12:153–7.
